US Edition
New leukemia drug offers hope for Iowa 4-year-old and others
IOWA, USA, JUL 20 – Blinatumomab lowers relapse rates in children with B-cell acute lymphoblastic leukemia from 10% to 4%, offering a less toxic alternative to traditional chemotherapy, doctors say.
- In Iowa sees Madi Seivert, who wore a flower backpack to carry blinatumomab through her port during her treatment, offering hope for young leukemia patients.
- Last year, clinical trials for blinatumomab ended early due to clear benefits, and the drug is now standard practice, binding to leukemia cells and activating T-cells.
- Relapse rates demonstrate significant improvement, `97 percent will go on and not have to worry about having leukemia again`, Dr. Wendy Woods said, highlighting treatment success.
- Ashley Seivert said `This is her survival` after seeing Madi Seivert in the maintenance phase, with her hair and energy returning.
- Families like the Seiverts are more hopeful than ever thanks to blinatumomab, and Dr. Wendy Woods anticipates it will reshape childhood leukemia treatment over the next decade.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
Coverage Details
Total News Sources17
Leaning Left0Leaning Right0Center16Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
